Pleiotropic effects of PI-3′ kinase/Akt signaling in human hepatoma cell proliferation and drug-induced apoptosis

Annals of the New York Academy of Sciences

Volumn 1090, Issue , 2006, Pages 1-17

  Alexia, Catherine ^a   Bras, Marlène ^a,b   Fallot, Guillaume ^a   Vadrot, Nathalie ^a   Daniel, Fanny ^a   Lasfer, Malika ^a   Tamouza, Houda ^a   Groyer, André ^a,c  

^a INSERM   (France)

^b INSTITUT PASTEUR   (France)

^c CENTRE DE RECHERCHE BIOMÉDICALE BICHAT BEAUJON CRB3   (France)

Author keywords

Apoptosis; Human hepatoma cells; Insulin like growth factors; PI 3 kinase signaling; Proliferation

Indexed keywords

2 MORPHOLINO 8 PHENYLCHROMONE; CASPASE 9; DOXORUBICIN; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; PROTEIN KINASE B BETA; SOMATOMEDIN C RECEPTOR; SOMATOMEDIN C;

APOPTOSIS; CELL CYCLE ARREST; CELL CYCLE G1 PHASE; CELL CYCLE S PHASE; CELL PROLIFERATION; CELL STIMULATION; CONFERENCE PAPER; CONTROLLED STUDY; CORRELATION ANALYSIS; DNA REPLICATION; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; HEPATOMA CELL; HUMAN; HUMAN CELL; LIVER CELL CARCINOMA; MITOCHONDRION; NUCLEOTIDE SEQUENCE; PLEIOTROPY; PROTEIN DEGRADATION; PROTEIN PHOSPHORYLATION; ARTICLE; DRUG EFFECT; ENZYMOLOGY; METABOLISM; PATHOLOGY; SIGNAL TRANSDUCTION; TUMOR CELL LINE;

MUS MUSCULUS;

1-PHOSPHATIDYLINOSITOL 3-KINASE; APOPTOSIS; CARCINOMA, HEPATOCELLULAR; CELL LINE, TUMOR; DNA REPLICATION; DOXORUBICIN; G1 PHASE; HUMANS; INSULIN-LIKE GROWTH FACTOR I; PROTO-ONCOGENE PROTEINS C-AKT; RECEPTOR, IGF TYPE 1; SIGNAL TRANSDUCTION;

EID: 34247606468     PISSN: 00778923     EISSN: 17496632     Source Type: Book Series    
DOI: 10.1196/annals.1378.001     Document Type: Conference Paper

References (60)

1. LIANG, T.J. et al. 1993. Viral pathogenesis of hepatocellular carcinoma in the United States. Hepatology 18: 1326-1333.
2. MACDONALD, G.A. 2001. Pathogenesis of hepatocellular carcinoma. Clin. Liver Dis. 5: 69-85.
3. LEVIN, B. & C. AMOS. 1995. Therapy of unresectable hepatocellular carcinoma. N. Engl. J. Med. 332: 1294-1296.
4. PITOT, H.C. 1998. Hepatocyte death in hepatocarcinogenesis. Hepatology 28: 1-5.
5. MICHALOPOULOS, G.K. & M.C. DEFRANCES. 1997. Liver regeneration. Science 276: 60-66.
6. HUMBEL, R.E. 1990. Insulin-like growth factors I and II. Eur. J. Biochem. 190: 445-462.
7. SCRIMGEOUR, A.G. et al. 1997. Mitogen-activated protein kinase and phosphatidylinositol 3-kinase pathways are not sufficient for insulin-like growth factor I-induced mitogenesis and tumorigenesis. Endocrinology 138: 2552-2558.
8. BASERGA, R. 1994. Oncogenes and the strategy of growth factors. Cell 79: 927-930.
9. KALEKO, M., W.J. RUTTER & A.D. MILLER. 1990. Overexpression of the human insulin-like growth factor I receptor promotes ligand-dependent neoplastic transformation. Mol. Cell. Biol. 10: 464-473.
10. SELL, C. et al. 1993. Simian virus 40 large tumor antigen is unable to transform mouse embryonic fibroblasts lacking type 1 insulin-like growth factor receptor. Proc. Natl. Acad. Sci. USA 90: 11217-11221.
11. RESNICOFF, M. et al. 1994. Rat glioblastoma cells expressing an antisense RNA to the insulin-like growth factor-1 (IGF-1) receptor are nontumorigenic and induce regression of wild-type tumors. Cancer Res. 54: 2218-2222.
12. KHANDWALA, H.M. et al. 2000. The effects of insulin-like growth factors on tumorigenesis and neoplastic growth. Endocr. Rev. 21: 215-244.
13. LEROITH, D. & C.T. ROBERTS, JR. 2003. The insulin-like growth factor system and cancer. Cancer Lett. 195: 127-137.
14. RESNICOFF, M. et al. 1995. The insulin-like growth factor I receptor protects tumor cells from apoptosis in vivo. Cancer Res. 55: 2463-2469.
15. SELL, C., R. BASERGA & R. RUBIN. 1995. Insulin-like growth factor I (IGF-I) and the IGF-I receptor prevent etoposide-induced apoptosis. Cancer Res. 55: 303-306.
16. ALEXIA, C. et al. 2004. An evaluation of the role of insulin-like growth factors (IGF) and of type-I IGF receptor signaling in hepatocarcinogenesis and in the resistance of hepatocarcinoma cells against drug-induced apoptosis. Biochem. Pharmacol. 68: 1003-1015.
17. CARO, J.F. et al. 1988. Insulin-like growth factor I binding in hepatocytes from human liver, human hepatoma, and normal, regenerating, and fetal rat liver. J. Clin. Invest. 81: 976-981.
18. CARIANI, E. et al. 1988. Differential expression of insulin-like growth factor II mRNA in human primary liver cancers, benign liver tumors, and liver cirrhosis. Cancer Res. 48: 6844-6849.
19. NARDONE, G. et al. 1996. Activation of fetal promoters of insulin-like growth factors II gene in hepatitis C virus-related chronic hepatitis, cirrhosis, and hepatocellular carcinoma. Hepatology 23: 1304-1312.
20. SCHARF, J.G., G. RAMADORI & F. DOMBROWSKI. 2000. Analysis of the IGF axis in preneoplastic hepatic foci and hepatocellular neoplasms developing after low-number pancreatic islet transplantation into the livers of streptozotocin diabetic rats. Lab. Invest. 80: 1399-1411.
21. SCHIRMACHER, P. et al. 1992. Reactivation of insulin-like growth factor II during hepatocarcinogenesis in transgenic mice suggests a role in malignant growth. Cancer Res. 52: 2549-2556.
22. SU, Q. et al. 1994. Expression of insulin-like growth factor II in hepatitis B, cirrhosis and hepatocellular carcinoma: its relationship with hepatitis B virus antigen expression. Hepatology 20: 788-799.
23. TAO, X. et al. 2000. Hepatitis B virus X protein activates expression of IGF-IR and VEGF in hepatocellular carcinoma cells. Zhonghua Gan Zang Bing Za Zhi 8: 161-163.
24. PRICE, J.A. et al. 2002. Insulin-like growth factor I is a comitogen for hepatocyte growth factor in a rat model of hepatocellular carcinoma. Hepatology 36: 1089-1097.
25. NISHIYAMA, M. & J.R. WANDS. 1992. Cloning and increased expression of an insulin receptor substrate-1-like gene in human hepatocellular carcinoma. Biochem. Biophys. Res. Commun. 183: 280-285.
26. TANAKA, S. et al. 1997. Biological effects of human insulin receptor substrate-1 overexpression in hepatocytes. Hepatology 26: 598-604.
27. MITSUI, H. et al. 2001. The MEK1-ERK map kinase pathway and the PI 3-kinase-Akt pathway independently mediate anti-apoptotic signals in HepG2 liver cancer cells. Int. J. Cancer 92: 55-62.
28. KOPS, G.J. et al. 2002. Forkhead transcription factor FOXO3a protects quiescent cells from oxidative stress. Nature 419: 316-321.
29. BURGERING, B.M. & G.J. KOPS. 2002. Cell cycle and death control: long live Forkheads. Trends Biochem. Sci. 27: 352-360.
30. NAKASHIO, A. et al. 2000. Prevention of phosphatidylinositol 3′-kinase-Akt survival signaling pathway during topotecan-induced apoptosis. Cancer Res. 60: 5303-5309.
31. WIDMANN, C., S. GIBSON & G.L. JOHNSON. 1998. Caspase-dependent cleavage of signaling proteins during apoptosis. A turn-off mechanism for anti-apoptotic signals. J. Biol. Chem. 273: 7141-7147.
32. TANG, D. et al. 2001. Akt is activated in response to an apoptotic signal. J. Biol. Chem. 276: 30461-30466. Epub 2001 June 8.
33. MADRID, L.V. et al. 2000. Akt suppresses apoptosis by stimulating the transactivation potential of the RelA/p65 subunit of NF-kappaB. Mol. Cell. Biol. 20: 1626-1638.
34. DIJKERS, P.F. et al. 2002. FKHR-L1 can act as a critical effector of cell death induced by cytokine withdrawal: protein kinase B-enhanced cell survival through maintenance of mitochondrial integrity. J. Cell. Biol. 156: 531-542.
35. DATTA, S.R. et al. 1997. Akt phosphorylation of BAD couples survival signals to the cell-intrinsic death machinery. Cell 91: 231-241.
36. DIEHL, J.A. et al. 1998. Glycogen synthase kinase-3beta regulates cyclin D1 proteolysis and subcellular localization. Genes Dev. 12: 3499-3511.
37. MEDEMA, R.H. et al. 2000. AFX-like Forkhead transcription factors mediate cell-cycle regulation by Ras and PKB through p27kip1. Nature 404: 782-787.
38. KOPS, G.J. et al. 2002b. Control of cell cycle exit and entry by protein kinase B-regulated forkhead transcription factors. Mol. Cell. Biol. 22: 2025-2036.
39. SHTIVELMAN, E., J. SUSSMAN & D. STOKOE. 2002. A role for PI 3-kinase and PKB activity in the G2/M phase of the cell cycle. Curr. Biol. 12: 919-924.
40. MITSIADES, C.S., N. MITSIADES & M. KOUTSILIERIS. 2004. The Akt pathway: molecular targets for anti-cancer drug development. Curr. Cancer Drug Targets 4: 235-256.
41. KAABACHE, T. et al. 1995. Direct solution hybridization of guanidine thiocyanatesolubilized cells for quantitation of mRNAs in hepatocytes. Anal. Biochem. 232: 225-230.
42. DURIEZ, P.J. & G.M. SHAH. 1997. Cleavage of poly(ADP-ribose) polymerase: a sensitive parameter to cell death. Biochem. Cell. Biol. 75: 337-349.
43. BUENDIA, M.A. 2000. Genetics of hepatocellular carcinoma. Semin. Cancer Biol. 10: 185-200.
44. HUYNH, H. et al. 2003. Over-expression of the mitogen-activated protein kinase (MAPK) kinase (MEK)-MAPK in hepatocellular carcinoma: its role in tumor progression and apoptosis. BMC Gastroenterol. 3: 19.
45. HAYAKAWA, J. et al. 1999. Inhibition of extracellular signal-regulated protein kinase or c-Jun N-terminal protein kinase cascade, differentially activated by cisplatin, sensitizes human ovarian cancer cell line. J. Biol. Chem. 274: 31648-31654.
46. FRASCA, F. et al. 1999. Insulin receptor isoform A, a newly recognized, high-affinity insulin-like growth factor II receptor in fetal and cancer cells. Mol. Cell. Biol. 19: 3278-3288.
47. LUND, P. et al. 2004. Autocrine inhibition of chemotherapy response in human liver tumor cells by insulin-like growth factor-II. Cancer Lett. 206: 85-96.
48. ALEXIA, C., M. LASFER & A. GROYER. 2004b. Role of constitutively activated and insulin-like growth ERK1/2 signaling in human hepatoma cell proliferation and apoptosis: evidence for heterogeneity of tumor cell lines. Ann. N. Y. Acad. Sci. 1030: 219-229.
49. COUTANT, A. et al. 2002. PI3K-FRAP/mTOR pathway is critical for hepatocyte proliferation whereas MEK/ERK supports both proliferation and survival. Hepatology 36: 1079-1088.
50. BRADER, S. & S.A. ECCLES. 2004. Phosphoinositide 3-kinase signaling pathways in tumor progression, invasion and angiogenesis. Tumori 90: 2-8.
51. BRENNAN, P. et al. 2002. Phosphatidylinositol 3-kinase is essential for the proliferation of lymphoblastoid cells. Oncogene 21: 1263-1271.
52. CHENEY, I.W. et al. 1999. Adenovirus-mediated gene transfer of MMAC1/PTEN to glioblastoma cells inhibits S phase entry by the recruitment of p27Kip1 into cyclin E/CDK2 complexes. Cancer Res. 59: 2318-2323.
53. KLIPPEL, A. et al. 1998. Activation of phosphatidylinositol 3-kinase is sufficient for cell cycle entry and promotes cellular changes characteristic of oncogenic transformation. Mol. Cell. Biol. 18: 5699-5711.
54. NELSEN, C.J. et al. 2001. Transient expression of cyclin D1 is sufficient to promote hepatocyte replication and liver growth in vivo. Cancer Res. 61: 8564-8568.
55. ALVAREZ, B. et al. 2001. Forkhead transcription factors contribute to execution of the mitotic programme in mammals. Nature 413: 744-747.
56. BACHELDER, R.E. et al. 1999. p53 inhibits alpha 6 beta 4 integrin survival signaling by promoting the caspase 3-dependent cleavage of AKT/PKB. J. Cell. Biol. 147: 1063-1072.
57. ROKUDAI, S. et al. 2000. Cleavage and inactivation of antiapoptotic Akt/PKB by caspases during apoptosis. J. Cell. Physiol. 182: 290-296.
58. LESLIE, N.R. et al. 2003. Redox regulation of PI 3-kinase signaling via inactivation of PTEN. EMBO J. 22: 5501-5510.
59. LAI, H.C. et al. 2003. Insulin-like growth factor-1 prevents loss of electrochemical gradient in cardiac muscle mitochondria via activation of PI 3 kinase/Akt pathway. Mol. Cell. Endocrinol. 205: 99-106.
60. BIJUR, G.N. & R.S. JOPE. 2003. Rapid accumulation of Akt in mitochondria following phosphatidylinositol 3-kinase activation. J. Neurochem. 87: 1427-1435.